SERB Pharmaceuticals Acquires RSDL Kit from Emergent BioSolutions for $75M
July 31, 2024
SERB Pharmaceuticals purchased the RSDL (Reactive Skin Decontamination Lotion) kit and related inventory, contracts and operations from Emergent BioSolutions for approximately $75 million, with an additional $5 million contingent milestone payment. The deal includes the Hattiesburg, Mississippi leased manufacturing facility and several site-based employees (who will join SERB), while Emergent's Winnipeg facility will continue to supply bulk lotion under a long-term supply agreement; Emergent said the divestiture supports debt reduction and portfolio rationalization.
- Buyers
- SERB Pharmaceuticals
- Targets
- RSDL (Reactive Skin Decontamination Lotion) kit
- Sellers
- Emergent BioSolutions Inc.
- Industry
- Medical Devices
- Location
- Maryland, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
SERB Pharmaceuticals Acquires Y-mAbs Therapeutics
September 16, 2025
Biotechnology
SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.
-
StatLab Medical Products Acquires Scientific Device Laboratory
April 25, 2024
Medical Devices
StatLab Medical Products, a McKinney, Texas-based manufacturer of medical diagnostic supplies, has acquired Scientific Device Laboratory (SDL), a Chicago-area maker of printed diagnostic slides and consumables for anatomic pathology and microbiology. The acquisition expands StatLab's microbiology capabilities, adds a U.S. R&D/manufacturing hub, and creates a dual-continent footprint for glass-slide manufacturing to better serve hospital, OEM and research customers.
-
Mitsui & Co. Acquires Dermaceutical Laboratories (D-LAB)
August 21, 2023
Consumer Products
Mitsui & Co., Ltd. has agreed to acquire all shares of Dermaceutical Laboratories, LLC (D-LAB), a Bergen County, New Jersey-based cosmetics ODM and contract manufacturer. Mitsui will position D-LAB as the core beauty & personal care (BPC) business in the Americas, leveraging Japanese technologies and Mitsui's procurement and global network to expand capabilities and scale in the U.S. market.
-
Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific
December 1, 2020
Pharmaceuticals
Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.
-
DermBiont Acquires SeylanMED to Expand Dermatology Pipeline
October 21, 2020
Biotechnology
DermBiont, a Boston-based clinical-stage precision dermatology company, has acquired SeylanMED, adding a targeted topical AKT inhibitor gel candidate for seborrheic keratosis to its pipeline. The acquisition expands DermBiont's therapeutic modalities and accelerates its objective to develop targeted topical treatments and live bacterial therapeutics for skin diseases.
-
CURE Pharmaceutical to Acquire Sera Labs for $20 Million
July 30, 2020
Consumer Products
CURE Pharmaceutical entered a memorandum of understanding to acquire 100% of privately held Sera Labs for $20 million in a deal composed primarily of CURE stock, with potential earn-outs of up to an additional $20 million. The acquisition adds Sera Labs' CBD-focused branded portfolio, DTC subscription model and retail/wholesale distribution (over 8,850 U.S. doors) to CURE's cGMP manufacturing and drug-delivery capabilities, with Sera Labs founder Nancy Duitch remaining in a leadership role.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.